Eli Lilly & Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
Lilly stopped development of the pill in August after data showed it harmed patients instead of helping them.
Even seven months after patients ceased the use of semagacestat, they still had more trouble with thinking, remembering and mental functioning than those who didn’t receive the medication, the Indianapolis-based company said today.
Source: http://www.bloomberg.com/news/2011-07-19/lilly-says-alzheimer-patients-on-failed-drug-didn-t-improve.html?cmpid=yhoo
